Could fewer shots keep myeloma at bay? new trial tests cost-saving approach
Disease control
Recruiting now
This phase 2 trial tests whether giving daratumumab less often (every 8 weeks, then every 16 weeks) along with lenalidomide can work as well as the standard schedule for multiple myeloma patients after a stem cell transplant. The goal is to reduce costs and clinic visits while ma…
Phase 2 • Sponsor: Eden Biltibo • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC